Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease Research Letter

   

Authors:	Boulad, F.; Zhang, J.; Yazdanbakhsh, K.; Sadelain, M.; Shi, P. A.
Title:	Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease
Abstract:	We present data from our study of plerixafor mobilization (NCT02193191) relevant to the question of whether further dose escalation of plerixafor can address inconsistent adequacy of CD34+ mobilization for gene therapy of sickle cell disease (SCD). We found that, in the same patient, higher plerixafor dosing was associated with higher fold increases in PB CD34+ count, but not necessarily higher absolute CD34+ counts. Variation in pre-apheresis absolute CD34+ counts was related to intra-individual variation in baseline PB CD34+ counts and inter-individual variation in responsiveness to plerixafor. Overall, our results support further studies of continued dose escalation of plerixafor for autologous HPC collection in SCD. © 2021 Elsevier Inc.
Keywords:	gene therapy; plerixafor; sickle cell disease; cxcr4; hematopoietic progenitor cell mobilization
Journal Title:	Blood Cells, Molecules, and Diseases
Volume:	90
ISSN:	1079-9796
Publisher:	Elsevier Inc.
Date Published:	2021-09-01
Start Page:	102588
Language:	English
DOI:	10.1016/j.bcmd.2021.102588
PROVIDER:	scopus
PUBMED:	34166998
PMCID:	PMC8338885
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108253111&doi=10.1016%2fj.bcmd.2021.102588&partnerID=40&md5=0d1dceb247d34227b0b00038b23d85c8
Notes:	Article -- Export Date: 1 July 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/182254